Caudle, Kelly E.Rettie, Allan E.Whirl-Carrillo, MichelleSmith, Lisa H.Mintzer, Scott E.Lee, Ming Ta MichaelKlein, Teri E.Callaghan, J. Thomas2016-02-262016-02-262014-11Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S. E., Lee, M. T. M., … Callaghan, J. T. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Clinical Pharmacology and Therapeutics, 96(5), 542–548. http://doi.org/10.1038/clpt.2014.1590009-9236https://hdl.handle.net/1805/8529Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large inter-patient variability partly due to genetic variations in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotype (also available on PharmGKB: www.pharmgkb.org).en-USPublisher PolicyAnticonvulsantsadministration & dosageCytochrome P-450 CYP2C9GeneticsHLA-B AntigensPhenytoinArticle